PE20251395A1 - Proteinas de fusion de hmpv de prefusion estabilizadas - Google Patents

Proteinas de fusion de hmpv de prefusion estabilizadas

Info

Publication number
PE20251395A1
PE20251395A1 PE2024002522A PE2024002522A PE20251395A1 PE 20251395 A1 PE20251395 A1 PE 20251395A1 PE 2024002522 A PE2024002522 A PE 2024002522A PE 2024002522 A PE2024002522 A PE 2024002522A PE 20251395 A1 PE20251395 A1 PE 20251395A1
Authority
PE
Peru
Prior art keywords
domain
relates
fusion proteins
hmpv
vector
Prior art date
Application number
PE2024002522A
Other languages
English (en)
Spanish (es)
Inventor
Johannes Petrus Maria Langedijk
Mark Johannes Gerardus Bakkers
Tina Ritschel
Jaroslaw Juraszek
Original Assignee
Msd Int Business Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Int Business Gmbh filed Critical Msd Int Business Gmbh
Publication of PE20251395A1 publication Critical patent/PE20251395A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PE2024002522A 2022-05-12 2023-05-11 Proteinas de fusion de hmpv de prefusion estabilizadas PE20251395A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22173131 2022-05-12
PCT/EP2023/062652 WO2023217988A1 (en) 2022-05-12 2023-05-11 Stabilized pre-fusion hmpv fusion proteins

Publications (1)

Publication Number Publication Date
PE20251395A1 true PE20251395A1 (es) 2025-05-22

Family

ID=81653543

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024002522A PE20251395A1 (es) 2022-05-12 2023-05-11 Proteinas de fusion de hmpv de prefusion estabilizadas

Country Status (16)

Country Link
EP (1) EP4522209A1 (enExample)
JP (1) JP2025521082A (enExample)
KR (1) KR20250010642A (enExample)
CN (1) CN119562826A (enExample)
AU (1) AU2023269241A1 (enExample)
CA (1) CA3253332A1 (enExample)
CL (1) CL2024003418A1 (enExample)
CO (1) CO2024015386A2 (enExample)
CR (1) CR20240493A (enExample)
DO (1) DOP2024000230A (enExample)
GE (1) GEAP202516650A (enExample)
IL (1) IL316911A (enExample)
JO (1) JOP20240256A1 (enExample)
MX (1) MX2024013959A (enExample)
PE (1) PE20251395A1 (enExample)
WO (1) WO2023217988A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026504862A (ja) 2023-01-18 2026-02-10 ファイザー・インク 呼吸器疾患に対するワクチン
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025144636A1 (en) * 2023-12-26 2025-07-03 The Scripps Research Institute ENGINEERED hMPV F PROTEIN IMMUNOGENS AND RELATED VACCINES
WO2025163460A2 (en) * 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
PL215165B1 (pl) 2002-04-25 2013-10-31 Crucell Holland Bv Rekombinowany wektor adenowirusowy oraz sposób wytwarzania rekombinowanego wektora adenowirusowego
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
JP7382230B2 (ja) 2016-10-17 2023-11-16 ヤンセン ファーマシューティカルズ，インコーポレーテッド 組み換えウイルスレプリコン系及びその使用
BR112019011661A2 (pt) 2016-12-05 2020-01-07 Synthetic Genomics, Inc. Composições e métodos para aumentar expressão de gene
US12559544B2 (en) * 2019-05-21 2026-02-24 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
CN116615235A (zh) * 2020-10-09 2023-08-18 得克萨斯州大学系统董事会 融合前稳定的hmpv f蛋白

Also Published As

Publication number Publication date
CA3253332A1 (en) 2023-11-16
CL2024003418A1 (es) 2025-08-01
JOP20240256A1 (ar) 2024-11-11
AU2023269241A1 (en) 2024-11-21
WO2023217988A1 (en) 2023-11-16
IL316911A (en) 2025-01-01
MX2024013959A (es) 2025-02-10
CO2024015386A2 (es) 2024-11-28
DOP2024000230A (es) 2025-02-16
GEAP202516650A (en) 2025-03-10
CN119562826A (zh) 2025-03-04
JP2025521082A (ja) 2025-07-08
KR20250010642A (ko) 2025-01-21
CR20240493A (es) 2025-01-29
EP4522209A1 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
PE20231439A1 (es) Proteinas f de hmpv estabilizadas por prefusion
Lavergne et al. Optimized deep-targeted proteotranscriptomic profiling reveals unexplored Conus toxin diversity and novel cysteine frameworks
BR112012022223A2 (pt) formulações de proteína concentrada e usos das mesmas
PE20160045A1 (es) Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
BR0307837A (pt) Anticorpos anti-abeta e seu uso
PE20191033A1 (es) PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
CY1116952T1 (el) Ειδικες και υψηλης συγγενειας δεσμευομενες πρωτεϊνες που περιλαμβανουν τροποποιημενες περιοχες sh3 κινασης fyn
PE20080397A1 (es) Proteinas de fusion del receptor de productos finales de glicacion avanzada (ragepor sus sigla en ingles), formulaciones, y metodos de uso de las mismas
BR112016003358A2 (pt) método para aumentar a expressão de proteínas codificadas por rna
MX2012002216A (es) Nueva endolisina obpgplys.
HRP20200036T1 (hr) Postupci liječenja tauopatije
BR112022022644A2 (pt) Composições de vírus adeno-associados compatíveis com espécies cruzadas e método de uso destas
BR112018017031A2 (pt) formulações de antagonista de il-6 e usos das mesmas
AR091155A1 (es) Composicion farmaceutica acuosa que contiene un agente terapeutico biologico y guanidina o un derivado de guanidina y una inyeccion que incluye la composicion
GEAP202516650A (en) Stabilized pre-fusion hmpv fusion proteins
CY1114724T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
MX2021004331A (es) Composiciones estables de semaglutida y usos de las mismas.
PE20190110A1 (es) Proteinas f de prefusion del vrs estabilizadas
AR066311A1 (es) Moleculas de anticuerpos anti proteina hsp90 fungica y acidos nucleicos que los codifican
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas
BR112013032088A2 (pt) "polipeptídeo, composição farmacêutica e seu uso"
MX2023009921A (es) Formulaciones de proteinas de fusion ace2-fc.
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina